Developer docs
API playgroundTry for free, no card

Search company profiles

MacuLogix

Full company profile

uuid0002h62

Namestring
MacuLogix
Websiteurl
maculogix.com
Company typeenum
Private
Founded yearint
2004
Short descriptiontext

MacuLogix developed the AdaptDx Pro, a diagnostic device that measures dark adaptation to detect early-stage age-related macular degeneration, serving ophthalmologists, optometrists, and retina specialists in the U.S. eye care market. The company was acquired by LumiThera Diagnostics in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiddletown, United States
HQ citystring
Middletown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ophthalmic diagnostics, dark adaptation testing, AMD detection devices, retinal diagnostic equipment, eye care instruments
Industry1 code
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Ophthalmic Goods Manufacturing339115
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic Diagnostic Devices
Social media profiles2 records
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MacuLogix develops and sells the AdaptDx Pro, a dark adaptation testing device that measures how quickly a patient's eyes adapt to darkness to detect and monitor age-related macular degeneration (AMD). The product is sold to eye care professionals including ophthalmologists, optometrists, and retina specialists for non-invasive screening and monitoring of retinal function. The product line was acquired by LumiThera Diagnostics in 2025.

Differentiator
Functional benefit
Problem solved
Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

LumiThera Diagnostics acquired MacuLogix in 2025, absorbing the AdaptDx product line and decommissioning the MacuLogix website. The AdaptDx Pro technology is now integrated into LumiThera's diagnostic portfolio for eye care.

Peers10 records
TypeDirect peer
Description

Specialist in ultra-widefield retinal imaging used by ophthalmologists and optometrists for AMD and diabetic retinopathy screening. Directly comparable as a retinal diagnostic vendor competing for in-office diagnostic capital in the same AMD care pathway.

TypeOthers
Description

Parent acquirer of MacuLogix and developer of photobiomodulation devices for ophthalmic conditions. Comparable as the strategic acquirer that now controls AdaptDx Pro commercialization, and as an adjacent player in the AMD therapeutic and diagnostic continuum.

3Carl Zeiss Meditec
TypeBroad incumbent
Description

Large incumbent ophthalmic device company offering diagnostic imaging, surgical microscopy, and laser systems to retina and refractive specialists. Comparable as a broad ophthalmic diagnostics incumbent whose products are integrated alongside AdaptDx Pro in retina practices.

TypeBroad incumbent
Description

Manufacturer of ophthalmic diagnostic and surgical equipment including OCT and fundus imaging. Comparable as a long-established diagnostic vendor whose retinal imaging products are part of the AMD diagnostic workflow.

TypeDirect peer
Description

Specialist in retinal imaging and visual field diagnostics for ophthalmic professionals. Comparable as a focused ophthalmic diagnostic equipment company with overlapping product categories used in AMD and glaucoma assessment.

TypeBroad incumbent
Description

Diversified ophthalmic equipment manufacturer offering OCT, fundus cameras, and diagnostic devices. Comparable as an incumbent diagnostic equipment vendor serving optometry and ophthalmology channels with overlapping AMD-relevant instrumentation.

TypeDirect peer
Description

Developer and manufacturer of ophthalmic diagnostic imaging systems (OCT, confocal microscopy) widely used in retina and glaucoma practices. Directly comparable as a specialist ophthalmic diagnostic equipment vendor serving the same eye-care professional customer base that buys AdaptDx Pro.

TypeRegional player
Description

Manufacturer of ophthalmic diagnostic imaging systems including retinal cameras used in screening and monitoring of AMD. Comparable as an ophthalmic diagnostic equipment vendor with overlapping AMD-relevant imaging offerings.

TypeEmerging player
Description

Ophthalmic device group with handheld fundus imaging and screening devices targeting primary care and optometry channels. Comparable as an emerging vendor expanding diagnostic access for retinal disease screening, including AMD, in non-specialist settings.

TypeDirect peer
Description

Provider of home-based AMD monitoring (ForeseeHome) and related diagnostic services for retina specialists. Directly comparable as a company focused on AMD detection and monitoring, addressing the same patient population and clinical decision points as AdaptDx Pro.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MacuLogix

Ophthalmic Diagnostic Devicesmaculogix.com

MacuLogix developed the AdaptDx Pro, a diagnostic device that measures dark adaptation to detect early-stage age-related macular degeneration, serving ophthalmologists, optometrists, and retina specialists in the U.S. eye care market. The company was acquired by LumiThera Diagnostics in 2025.

MacuLogix firmographics

Firmographics
Name
MacuLogix
Website
https://maculogix.com
Company type
Private
Founded year
2004
Operating status
Acquired
Headcount range
11–50 employees
Short description
MacuLogix developed the AdaptDx Pro, a diagnostic device that measures dark adaptation to detect early-stage age-related macular degeneration, serving ophthalmologists, optometrists, and retina specialists in the U.S. eye care market. The company was acquired by LumiThera Diagnostics in 2025.
Ownership category
akta.pro rank

MacuLogix industry classification

Industry
Product category
Ophthalmic Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Ophthalmic Goods Manufacturing (339115)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic diagnostics
  • Dark adaptation testing
  • AMD detection devices
  • Retinal diagnostic equipment
  • Eye care instruments

Where MacuLogix is headquartered

Location

Headquarters

HQ city
Middletown
HQ country
United States
HQ region
North America

Markets served

MacuLogix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

MacuLogix product offering

Product offering

Core offering

MacuLogix develops and sells the AdaptDx Pro, a dark adaptation testing device that measures how quickly a patient's eyes adapt to darkness to detect and monitor age-related macular degeneration (AMD). The product is sold to eye care professionals including ophthalmologists, optometrists, and retina specialists for non-invasive screening and monitoring of retinal function. The product line was acquired by LumiThera Diagnostics in 2025.

Differentiator

Problem solved

Functional benefit

Companies that use MacuLogix

Customer profile

Segments1 record

Ideal customer profiles1 record

MacuLogix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MacuLogix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LumiThera DiagnosticsflagshipStrategic or Co-development Partner · 1 January 2025LumiThera Diagnostics acquired MacuLogix in 2025, absorbing the AdaptDx product line and decommissioning the MacuLogix website. The AdaptDx Pro technology is now integrated into LumiThera's diagnostic portfolio for eye care.

MacuLogix competitors and assessment

Company assessment

Direct peers

  • Optos (Nikon Healthcare): Specialist in ultra-widefield retinal imaging used by ophthalmologists and optometrists for AMD and diabetic retinopathy screening. Directly comparable as a retinal diagnostic vendor competing for in-office diagnostic capital in the same AMD care pathway.
  • CenterVue (iCare): Specialist in retinal imaging and visual field diagnostics for ophthalmic professionals. Comparable as a focused ophthalmic diagnostic equipment company with overlapping product categories used in AMD and glaucoma assessment.
  • Heidelberg Engineering: Developer and manufacturer of ophthalmic diagnostic imaging systems (OCT, confocal microscopy) widely used in retina and glaucoma practices. Directly comparable as a specialist ophthalmic diagnostic equipment vendor serving the same eye-care professional customer base that buys AdaptDx Pro.
  • Notal Vision: Provider of home-based AMD monitoring (ForeseeHome) and related diagnostic services for retina specialists. Directly comparable as a company focused on AMD detection and monitoring, addressing the same patient population and clinical decision points as AdaptDx Pro.

Others

  • LumiThera: Parent acquirer of MacuLogix and developer of photobiomodulation devices for ophthalmic conditions. Comparable as the strategic acquirer that now controls AdaptDx Pro commercialization, and as an adjacent player in the AMD therapeutic and diagnostic continuum.

Broad incumbents

  • Carl Zeiss Meditec: Large incumbent ophthalmic device company offering diagnostic imaging, surgical microscopy, and laser systems to retina and refractive specialists. Comparable as a broad ophthalmic diagnostics incumbent whose products are integrated alongside AdaptDx Pro in retina practices.
  • Nidek: Manufacturer of ophthalmic diagnostic and surgical equipment including OCT and fundus imaging. Comparable as a long-established diagnostic vendor whose retinal imaging products are part of the AMD diagnostic workflow.
  • Topcon Healthcare: Diversified ophthalmic equipment manufacturer offering OCT, fundus cameras, and diagnostic devices. Comparable as an incumbent diagnostic equipment vendor serving optometry and ophthalmology channels with overlapping AMD-relevant instrumentation.

Regional players

  • Kowa Optimed: Manufacturer of ophthalmic diagnostic imaging systems including retinal cameras used in screening and monitoring of AMD. Comparable as an ophthalmic diagnostic equipment vendor with overlapping AMD-relevant imaging offerings.

Emerging players

  • Revenio Group (iCare / Optomed): Ophthalmic device group with handheld fundus imaging and screening devices targeting primary care and optometry channels. Comparable as an emerging vendor expanding diagnostic access for retinal disease screening, including AMD, in non-specialist settings.

Market position

Customer concentration

MacuLogix social profiles

Digital presence

MacuLogix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MacuLogix leadership team

Management profile

Number of profiles

Profiles3 records

MacuLogix funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MacuLogix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MacuLogix

What does MacuLogix do?

MacuLogix develops and sells the AdaptDx Pro, a dark adaptation testing device that measures how quickly a patient's eyes adapt to darkness to detect and monitor age-related macular degeneration (AMD). The product is sold to eye care professionals including ophthalmologists, optometrists, and retina specialists for non-invasive screening and monitoring of retinal function. The product line was acquired by LumiThera Diagnostics in 2025.

When was MacuLogix founded?

MacuLogix was founded in 2004. It employs 11 to 50 people.

Where is MacuLogix based?

MacuLogix is headquartered in Middletown, United States, in the North America region.

Who are MacuLogix's main competitors?

Direct peers on record are Optos (Nikon Healthcare), CenterVue (iCare), Heidelberg Engineering and Notal Vision. LumiThera is listed as an others. Broad incumbents are Carl Zeiss Meditec, Nidek and Topcon Healthcare. Kowa Optimed is listed as a regional player. Revenio Group (iCare / Optomed) is listed as an emerging player.

Does MacuLogix have an API?

No public API is recorded for MacuLogix.

What industry is MacuLogix in?

MacuLogix's product category is Ophthalmic Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLumiThera, Inc. kündigt Kauf von MacuLogix Assets anLumiThera Inc. announced the purchase of assets from MacuLogix, Inc. through its wholly-owned subsidiary. MacuLogix is a leader in early diagnosis of dry age-related macular degeneration (AMD) and developer of the AdaptDx Pro portable dark adaptometer, which enables eye doctors to measure dark adaptation and diagnose dry AMD earlier than other technologies. The acquisition complements LumiThera's Valeda Light Delivery System product line, following a previous March 2022 acquisition of Diopsys VEP and ERG technology, creating a combined diagnostic, treatment, and monitoring platform for dry AMD patients.PR NewswireLumiThera, Inc. Anuncia la compra de activos de MacuLogixLumiThera Inc. announced the acquisition of assets from MacuLogix, Inc., a company specializing in early diagnosis of Age-Related Macular Degeneration (AMD). MacuLogix developed the AdaptDX Pro®, a portable dark adaptometer that enables eye care professionals to measure dark adaptation for diagnosing dry AMD earlier than other technologies, with over 1 million tests performed and approximately 200,000 patients diagnosed. The acquisition combines MacuLogix's diagnostic technology with LumiThera's existing treatment and monitoring platforms to create a comprehensive solution for dry AMD patients.PR NewswireLumiThera, Inc. Announces Purchase of MacuLogix AssetsLumiThera, Inc. announced the acquisition of MacuLogix assets through its wholly owned subsidiary to integrate the AdaptDX Pro dark adaptometer into its product portfolio. This move follows LumiThera's recent positive LIGHTSITE III clinical trial data for its Valeda treatment system and supports its strategy to combine diagnosis, treatment, and monitoring platforms for dry Age-related Macular Degeneration.Mpo-magLumiThera Acquires MacuLogix, an AMD Diagnosis FirmLumiThera has acquired MacuLogix, a firm specializing in the diagnosis of dry age-related macular degeneration (AMD) and developer of the AdaptDX Pro dark adaptometer. This acquisition complements LumiThera's existing treatment technologies, such as the Valeda light delivery system, to create a comprehensive diagnostic and therapeutic platform for eye care professionals. The move follows recent positive clinical data from LumiThera's LIGHTSITE III study and the earlier acquisition of Diopsys vision testing technology.PR NewswireTheia, AdaptDx Pro's On-Board AI Technician, Now Speaks in Multiple Languages to Enable More Inclusive Dark Adaptation Testing in Eye Care PracticesMacuLogix, Inc. announced a major software upgrade for its AdaptDx Pro portable dark adaptometer, enabling the onboard AI technician, Theia, to provide instructions and interfaces in multiple languages including English, Spanish, French, Italian, and German. This update allows eye care professionals to operate the device in one language while delivering patient guidance in their native tongue to improve communication and inclusivity in age-related macular degeneration testing.PR NewswireNew Annual Report Demonstrates How Dark Adaptation Makes AMD Management Easy, Accurate and Profitable -- in Virtually Any Eye Care SettingMacuLogix, Inc. announced the publication of its fourth annual report, "Practical Opportunities in AMD Management," in the September 2020 issue of Review of Optometry, showcasing how the company's dark adaptation technology helps eye care professionals diagnose and manage age-related macular degeneration. The AdaptDx Pro, a self-contained wearable headset powered by artificial intelligence, has been adopted by over 1,000 eye care professionals worldwide and enables detection of AMD up to three years before clinical identification. The report includes real-world implementation accounts from seven optometrists who have integrated the technology into their practices.PR NewswireMacuLogix Introduces the AdaptDx Pro, Guided by TheiaMacuLogix announced the launch of the AdaptDx Pro, a wearable dark adaptation testing device for age-related macular degeneration (AMD) that integrates an AI-driven technician named Theia. This new headset allows eye care professionals to perform reliable AMD diagnostics in-office without requiring a dark room or external computer.NewswireMacuLogix Introduces the AdaptDx Pro, Guided by TheiaMacuLogix introduced the AdaptDx Pro, a wearable dark adaptation device guided by Theia AI, for AMD detection. The device is 90% specific and sensitive to AMD, and the company offers upgrade options for existing AdaptDx owners.NewswireMacuLogix Hires Christine W. Silverberg as Director of National AccountsMacuLogix appointed Christine Silverberg as Director of National Accounts to lead business development and partnerships for Dark Adaptation testing. She brings 15 years of sales experience from companies like FUJIFILM and Hill-Rom. The role aims to make the testing more available to consumers across the US.Newswire'Practical Strategies for Preventing Blindness Caused by AMD' Offers Clear Framework on How to Manage AMD in Optometric PracticeMacuLogix published 'Practical Strategies for Preventing Blindness Caused by AMD' at Academy 2019, featuring an AMD Manifesto with five practice guidelines. The report includes expert articles on diagnosis, supplementation, and dark adaptation testing, aiming to modernize AMD care.